ArticleIranian journal of pathology2026
ARID1A, β-Catenin and P53 Immunohistochemical Expression: Diagnostic Value in Endometrial Carcinoma and Premalignant Endometrial Lesions.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Although the role of atypical endometrial hyperplasia as a precursor lesion of endometrial carcinoma (EC) has been well documented, the molecular pathogenesis underlying malignant progression remains largely unclear. The current work aimed to evaluate the role of ARID1A, β-catenin, and p53 expression in differentiating between endometrial carcinoma and precancerous endometrial lesions. Methods: Forty-eight cases of endometrial carcinoma (EC) and 14 cases of atypical endometrial hyperplasia (AEH) were evaluated for immunohistochemical expression of ARID1A, β-catenin, and p53. Results: Combining ARID1A and β-catenin enhanced diagnostic performance. For distinguishing endometrioid carcinoma from AEH/EIN, the combination achieved a sensitivity of 70% and an accuracy of 70.5%, though with lower specificity (71.4%) than ARID1A alone. For differentiating endometrioid from non-endometrioid carcinoma, the combined markers showed higher sensitivity (86.7%) and accuracy (83.3%) but reduced specificity (77.8%) compared with ARID1A alone. The triple combination of ARID1A, β-catenin, and p53 increased specificity (92.9%) for distinguishing endometrioid carcinoma from AEH/EIN compared with individual markers or the ARID1A-β-catenin double panel, but markedly decreased sensitivity (53.3%). In contrast, for differentiating endometrioid from non-endometrioid carcinoma, the triple panel achieved superior sensitivity (87.7%), specificity (94.4%), and accuracy (91.5%) relative to each marker alone or the ARID1A-β-catenin combination. Conclusion: The role of ARID1A, β-catenin, and p53 in the diagnosis of endometrial carcinoma (EC) is complex, as these markers are involved in distinct but interconnected molecular pathways that contribute to tumorigenesis. Their combined analysis can help classify endometrial carcinoma subtypes and may guide personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.